Page 6 of 13
Self-Amplifying mRNA Vaccine Receives EUA Nod From Indian Regulators
Messenger RNA (mRNA) technology has been central to the global response to Covid-19, enabling rapid manufacture of effective vaccines. But the virus continues to evolve, learning to out-maneuver prior immunity, whether from infection or from vaccination.
October 17, 2022
A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge
2022 | Suschak, J
Tags: Clinical, DNA, Infectious Diseases, Non-Human, Stratis, Tropis, VEEV
October 5, 2022
Precision of dose and depth delivery with our needle-free jet injections is our highest priority and we have the Quality credentials to prove it.
Precision of dose and depth delivery with our needle-free jet injections is our highest priority and we have the Quality credentials to prove it.At PharmaJet, we are proud to display the framed certificate indicating we are the first and only Needle-free Injection Systems (NFIS) to achieve WHO prequalification (E008/050, E008/071), which is a requirement for...
October 4, 2022
PharmaJet to present latest research showing superior immunogenicity with their Needle-free Systems at Five Conferences in October
GOLDEN, Colo. — September 27, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that their latest research results will be presented at five upcoming conferences in October:
Tags: COVID-19, DNA, Events, mRNA, Nucleic Acid, Stratis, Tropis
September 23, 2022
PharmaJet presents latest research showing Benefits of Needle-free at Military Health System Research Symposium
GOLDEN, Colo. — September 12, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the Military Health System Research Symposium (MHSRS) on September 13, 2022. The presentation, entitled Advancement of a Next Generation Needle-Free Injection Device for Effective Delivery of the Venezuelan Equine Encephalitis Virus DNA Vaccine, will be presented by Erin Spiegel, Ph.D., Vice President of Clinical and Regulatory Affairs at PharmaJet. The MHSRS is the foremost scientific meeting for the Department of Defense providing a venue for presenting new scientific knowledge resulting from military-unique research and development.
Tags: DNA, Events, Infectious Diseases, Stratis, Tropis, VEEV
September 7, 2022
WHO selects PharmaJet Needle-free Injection System for Million+ Polio Vaccination Campaign
GOLDEN, Colo. — August 31, 2022 — PharmaJet® , a company who has developed and commercialized an intradermal needle-free platform to more effectively administer drugs and biologics, today announced that the World Health Organization (WHO) selected the PharmaJet Tropis® Needle-free Injection System (NFIS) for large polio vaccination campaigns in Pakistan as part of a broader effort of coordinated campaigns between Pakistan and Afghanistan. Over 2.7 million children have been targeted for this program so far using the PharmaJet Tropis® NFIS.
August 18, 2022
University of Adelaide begins Human Trial of Omicron COVID vaccine booster using PharmaJet Needle-free System
GOLDEN, Colo. — August 16, 2022 — PharmaJet® , a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis® Needle-free Injection System (NFIS).
Tags: COVID-19, DNA, Nucleic Acid, Tropis
August 3, 2022
PharmaJet Partner, Scancell, Announces Phase 2 Melanoma DNA Vaccine Trial will include Needle-free Delivery
GOLDEN, Colo. — August 2, 2022 — PharmaJet® , a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that its partner, Scancell, will include needle-free delivery of their Phase 2 clinical study for treatment of patients with advanced melanoma.
Tags: DNA, Melanoma, Nucleic Acid, Stratis
July 21, 2022
PharmaJet presents latest research showing Benefits of Needle-free at mRNA-Based Therapeutics Summit
GOLDEN, Colo. — July 19, 2022 — PharmaJet® , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022. The presentation, entitled Advances in mRNA vaccines and therapeutics delivery with PharmaJet Needle-free Injection Systems, will be presented by Carmen Ledesma-Feliciano, DVM, PhD, DACLAM, Clinical Device Specialist at PharmaJet. This event, which takes place in Boston, will convene mRNA experts to highlight emerging tools and technologies that support the development of scalable and commercially viable mRNA-based therapeutics.
Tags: COVID-19, Events, mRNA, Nucleic Acid, Rabies, Stratis, Tropis, Tropis/Stratis
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
2022 Houser, KV
Tags: Clinical, DNA, Phase 3, Respiratory Viruses, Tropis
July 8, 2022
PharmaJet Expands Manufacturing Capacity to meet Demand for its Needle-free Injection System
PharmaJet Expands Manufacturing Capacity to meet Demand for its Needle-free Injection SystemIt’s all about teamwork, collaboration, and QualityPharmaJet has expanded its manufacturing capacity to meet the increasing demand as our partners commercialize their vaccines and pharmaceutical products. Read more below about the extraordinary effort and commitment our Quality and Operations teams and our collaborators demonstrated...
Our Blogs
Our Blogs Previous 1 … 5 6 7 … 13 NextWhy Delivery Matters for Pandemic ReadinessRecent crises have shown that pandemics don’t simply strain health systems—they disrupt entire societies. Supply chains falter under global demand. Regulatory processes slow when speed is most vital. Health systems run short on qualified vaccinators. And affordability barriers delay access...
July 8, 2022
Events
Events 2026 Oct 29-30 Partnership Opportunities in Drug Delivery Boston, Massachusetts Schedule a Meeting With Us
July 7, 2022
PharmaJet presents multiple partners’ data demonstrating superior immunogenicity with their Needle-free Systems at BIO International Convention
GOLDEN, Colo. — July 5, 2022—PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, today announced that their latest research results were presented at the BIO International Convention in June. The presentation, entitled Improved Vaccine and Therapeutic Performance…without the Jab, was presented by Paul LaBarre, MS, MBA, Vice President Global Business Development at PharmaJet, Inc.
Tags: COVID-19, DNA, Events, mRNA, Nucleic Acid, Rabies, Tropis
June 28, 2022
PharmaJet Partner, Nykode Therapeutics, Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial
GOLDEN, Colo. — June 21, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, Nykode Therapeutics announced positive interim results from its phase 2 trial of their novel candidate, VB10.16, in combination with checkpoint inhibitor atezolizumab for treating ad-vanced cervical cancer. The DNA-based therapeutic cancer vaccine is delivered with the PharmaJet needle-free injection technology.
Tags: DNA, HPV, Nucleic Acid, Stratis
June 14, 2022
The Lancet Publication Shows Benefits of PharmaJet Needle-free delivery for World’s First Commercialized Plasmid DNA COVID-19 Vaccine
GOLDEN, Colo. — June 7, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that the phase 3 clinical study sponsored by their partner, Zydus Lifesciences, has been published in The Lancet. The peer-reviewed article, entitled Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomized, double-blind, placebo-controlled study in India, features ZyCoV-D, the world’s first plasmid-DNA vaccine approved for use in humans, delivered exclusively by the PharmaJet Tropis® Intradermal Needle-free Injection System.
Tags: COVID-19, DNA, Nucleic Acid, Tropis
June 3, 2022
PharmaJet partner, Institute for Molecular Medicine, launches clinical trial for the first in human Alzheimer’s DNA Vaccine
GOLDEN, Colo. — May 24, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, the Institute for Molecular Medicine (IMM) was awarded a $12 Million grant from the National Institute on Aging (NIA) division of the National Institutes of Health (NIH). The grant supports clinical trials of their beta-amyloid vaccines based on DNA and recombinant protein for the prevention of Alzheimer’s disease (AD). A phase 1 clinical study in the U.S. is expected to begin in second quarter 2022 and the vaccine will be exclusively delivered by the PharmaJet Tropis® Needle-free Injection System.
Tags: Alzheimer’s, DNA, Nucleic Acid, Tropis
May 13, 2022
PharmaJet Announces Addition of Darin Zehrung as Chief Business Development Officer
GOLDEN, Colo. — May 10, 2022 — PharmaJet ®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that Darin Zehrung has joined the executive leadership team as Chief Business Development Officer. Mr. Zehrung is a global health business executive with over 25 years of technical, business and research leadership experience, most notably with PATH, the global nonprofit improving public health. In this role he will lead the development of new business for the Company, advancing strategic partnerships with global health agencies such as GAVI, WHO, UNICEF, and CEPI, and establishing partnerships with private/public companies in the global health market to advance commercial opportunities.
Tags: Other, Stratis, Tropis, Tropis/Stratis
May 5, 2022
PharmaJet presents partner data demonstrating superior immunogenicity with their Needle-free Systems at World Vaccine Congress
GOLDEN, Colo. — April 27, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that their latest research results were presented at the World Vaccine Congress on April 20. The presentation, entitled Benefits of Vaccine and Therapeutics Delivery with PharmaJet’s Needle-free Injection Systems, was presented by Carmen Ledesma-Feliciano, DVM, PhD, DACLAM, Clinical Device Specialist at PharmaJet, Inc.
Tags: DNA, Events, mRNA, Nucleic Acid, Stratis, Tropis, Tropis/Stratis
April 22, 2022
PharmaJet Launches New Interactive Website
GOLDEN, Colo. — April 13, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced the launch of their new website aimed at expanding partner support with on-line tools for more rapid and efficient pharmaceutical development. Focusing on PharmaJet’s mission, “Enabling greater access to life-improving pharmaceuticals”, the new website provides a better user experience, highlighting the improved performance that can be achieved with needle-free delivery and providing existing and potential partners easy access to valuable information and resources to help them make informed decisions.
Tags: Stratis, Tropis, Tropis/Stratis
April 13, 2022
Page 6 of 13